BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1150 related articles for article (PubMed ID: 28447181)

  • 21. Exendin-4 Protects against Hyperglycemia-Induced Cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway.
    Wei H; Bu R; Yang Q; Jia J; Li T; Wang Q; Chen Y
    J Diabetes Res; 2019; 2019():8905917. PubMed ID: 31886288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney.
    Ke Q; Shi C; Lv Y; Wang L; Luo J; Jiang L; Yang J; Zhou Y
    FASEB J; 2022 Jan; 36(1):e22078. PubMed ID: 34918381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway.
    Zhang J; Huang L; Shi X; Yang L; Hua F; Ma J; Zhu W; Liu X; Xuan R; Shen Y; Liu J; Lai X; Yu P
    Aging (Albany NY); 2020 Nov; 12(23):24270-24287. PubMed ID: 33232283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload.
    Shi L; Zhu D; Wang S; Jiang A; Li F
    Am J Hypertens; 2019 Apr; 32(5):452-459. PubMed ID: 30689697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of AMPK/mTOR-driven autophagy and inhibition of NLRP3 inflammasome by saxagliptin ameliorate ethanol-induced gastric mucosal damage.
    Arab HH; Ashour AM; Gad AM; Mahmoud AM; Kabel AM
    Life Sci; 2021 Sep; 280():119743. PubMed ID: 34166711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
    Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
    Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombin receptor PAR4 drives canonical NLRP3 inflammasome signaling in the heart.
    Fender AC; Kleeschulte S; Stolte S; Leineweber K; Kamler M; Bode J; Li N; Dobrev D
    Basic Res Cardiol; 2020 Jan; 115(2):10. PubMed ID: 31912235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2α signaling pathway in arrhythmogenic cardiomyopathy.
    Yang Z; Li T; Xian J; Chen J; Huang Y; Zhang Q; Lin X; Lu H; Lin Y
    FASEB J; 2022 Jul; 36(7):e22410. PubMed ID: 35713937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):55-56. PubMed ID: 29635266
    [No Abstract]   [Full Text] [Related]  

  • 30. Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome.
    Seo JB; Choi YK; Woo HI; Jung YA; Lee S; Lee S; Park M; Lee IK; Jung GS; Park KG
    Diabetes Metab J; 2019 Dec; 43(6):830-839. PubMed ID: 30877711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.
    Vilsbøll T; Ekholm E; Johnsson E; Garcia-Sanchez R; Dronamraju N; Jabbour SA; Lind M
    Diabetes Obes Metab; 2020 Jun; 22(6):957-968. PubMed ID: 32003150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DPP4 inhibition mitigates ANG II-mediated kidney immune activation and injury in male mice.
    Nistala R; Meuth AI; Smith C; An J; Habibi J; Hayden MR; Johnson M; Aroor A; Whaley-Connell A; Sowers JR; McKarns SC; Bender SB
    Am J Physiol Renal Physiol; 2021 Mar; 320(3):F505-F517. PubMed ID: 33522410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench.
    Shih JY; Lin YW; Fisch S; Cheng JT; Kang NW; Hong CS; Chen ZC; Chang WT
    Diabetes; 2021 Jan; 70(1):262-267. PubMed ID: 33115828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE
    Leng W; Ouyang X; Lei X; Wu M; Chen L; Wu Q; Deng W; Liang Z
    Mediators Inflamm; 2016; 2016():6305735. PubMed ID: 28104929
    [No Abstract]   [Full Text] [Related]  

  • 35. Histone deacetylase (HDAC) inhibition improves myocardial function and prevents cardiac remodeling in diabetic mice.
    Chen Y; Du J; Zhao YT; Zhang L; Lv G; Zhuang S; Qin G; Zhao TC
    Cardiovasc Diabetol; 2015 Aug; 14():99. PubMed ID: 26245924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
    Frías JP; Maaske J; Suchower L; Johansson L; Hockings PD; Iqbal N; Wilding JPH
    Diabetes Obes Metab; 2022 Jan; 24(1):61-71. PubMed ID: 34514692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes.
    Gangadharan Komala M; Gross S; Zaky A; Pollock C; Panchapakesan U
    Nephrology (Carlton); 2016 May; 21(5):423-31. PubMed ID: 26375854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus.
    Hu S; Deng X; Ma Y; Li Z; Wang Y; Wang Y
    Appl Health Econ Health Policy; 2021 Jan; 19(1):69-79. PubMed ID: 32783086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salidroside alleviates diabetic neuropathic pain through regulation of the AMPK-NLRP3 inflammasome axis.
    Zheng T; Wang Q; Bian F; Zhao Y; Ma W; Zhang Y; Lu W; Lei P; Zhang L; Hao X; Chen L
    Toxicol Appl Pharmacol; 2021 Apr; 416():115468. PubMed ID: 33639149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluorofenidone attenuates interleukin-1β production by interacting with NLRP3 inflammasome in unilateral ureteral obstruction.
    Zheng L; Zhang J; Yuan X; Tang J; Qiu S; Peng Z; Yuan Q; Xie Y; Mei W; Tang Y; Meng J; Hu G; Tao L
    Nephrology (Carlton); 2018 Jun; 23(6):573-584. PubMed ID: 28437591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.